Checkpoint Therapeutics (CKPT) News Today $2.57 -0.09 (-3.38%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 6:42 PM | marketwatch.comCheckpoint Therapeutics Shares Rise After FDA Accepts Resubmission of CosibelimabJuly 25 at 6:42 PM | markets.businessinsider.comCheckpoint Therapeutics Says FDA Accepted BLA Resubmission Of CosibelimabJuly 25 at 7:30 AM | globenewswire.comCheckpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaJuly 15, 2024 | globenewswire.comGC Cell and Checkpoint Therapeutics Advance Collaborative Cancer ResearchJuly 3, 2024 | marketbeat.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Down 6.1% in JuneCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a large decrease in short interest in June. As of June 15th, there was short interest totalling 3,820,000 shares, a decrease of 6.1% from the May 31st total of 4,070,000 shares. Approximately 13.1% of the shares of the company are sold short. Based on an average daily trading volume, of 377,200 shares, the days-to-cover ratio is currently 10.1 days.July 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabJune 29, 2024 | insidertrades.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 13,038 SharesJune 28, 2024 | marketbeat.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $26,858.28 in StockCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 13,038 shares of the business's stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares in the company, valued at approximately $1,384,703.16. The sale was disclosed in a legal filing with the SEC, which is available through this link.June 24, 2024 | globenewswire.comCheckpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionJune 5, 2024 | globenewswire.comCHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 3, 2024 | globenewswire.comCKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPTJune 3, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)June 3, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointJune 3, 2024 | globenewswire.comCKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 31, 2024 | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 30, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 29, 2024 | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPTMay 29, 2024 | msn.comCheckpoint Zoo Documentary Poster Sets Up A 2022 Ukrainian Animal Rescue StoryMay 28, 2024 | markets.businessinsider.comIMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 28, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 27, 2024 | markets.businessinsider.comUPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 26, 2024 | sfgate.com2 Arrested For Driving Under The Influence, 32 Ticketed At CheckpointMay 24, 2024 | prnewswire.comFINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 24, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 23, 2024 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 22, 2024 | prnewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPTMay 20, 2024 | stockhouse.comUPCOMING CKPT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Checkpoint Therapeutics, Inc. Investors to Join the Class Action Lawsuit!May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Checkpoint Therapeutics Despite FDA Setback: Solid Clinical Data Fuels Optimism for 2024 Market EntryMay 16, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 16, 2024 | marketbeat.comCheckpoint Therapeutics (NASDAQ:CKPT) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $34.00 target price on shares of Checkpoint Therapeutics in a research note on Thursday.May 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 15, 2024 | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPTMay 15, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 14, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 13, 2024 | globenewswire.comCheckpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 12, 2024 | finance.yahoo.comCheckpoint Therapeutics First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)May 10, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 10, 2024 | finanznachrichten.deCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 10, 2024 | investorplace.comCKPT Stock Earnings: Checkpoint Therapeutics Misses EPS for Q1 2024May 10, 2024 | globenewswire.comCheckpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 8, 2024 | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPTMay 8, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 7, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointMay 2, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 1, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad)In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. Watch Alex's "Next Magnificent Seven" presentation now. CKPT Media Mentions By Week CKPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CKPT News Sentiment▼0.390.62▲Average Medical News Sentiment CKPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CKPT Articles This Week▼42▲CKPT Articles Average Week Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Leap Therapeutics News Today Vanda Pharmaceuticals News Today Q32 Bio News Today Xeris Biopharma News Today AC Immune News Today Kamada News Today Inozyme Pharma News Today Nkarta News Today XOMA News Today Amarin News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CKPT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CKPT Stock Alerts